435 related articles for article (PubMed ID: 9918312)
21. A single cycle of 2-chlorodeoxyadenosine results in complete remission in the majority of patients with hairy cell leukemia.
Tallman MS; Hakimian D; Variakojis D; Koslow D; Sisney GA; Rademaker AW; Rose E; Kaul K
Blood; 1992 Nov; 80(9):2203-9. PubMed ID: 1358262
[TBL] [Abstract][Full Text] [Related]
22. Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience.
Öngören Ş; Eşkazan AE; Berk S; Elverdi T; Salihoğlu A; Ar MC; Başlar Z; Aydın Y; Tüzüner N; Soysal T
Turk J Haematol; 2017 Dec; 34(4):291-299. PubMed ID: 29199176
[TBL] [Abstract][Full Text] [Related]
23. Treatment of hairy cell leukemia-variant with cladribine.
Tetreault SA; Robbins BA; Saven A
Leuk Lymphoma; 1999 Oct; 35(3-4):347-54. PubMed ID: 10706459
[TBL] [Abstract][Full Text] [Related]
24. Retrospective analysis of 34 cases of hairy cell leukemia treated with interferon-alpha and/or 2-chlorodeoxyadenosine.
Zaja F; Fanin R; Silvestri F; Russo D; Infanti L; Baccarani M
Haematologica; 1997; 82(4):468-70. PubMed ID: 9299866
[TBL] [Abstract][Full Text] [Related]
25. Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment.
Robak T; Boński JZ; Kasznicki M; Góra-Tybor J; Hellmann A; Konopka L; Dmoszyńska A; Dwilewicz-Trojaczek J; Wołowiec D;
Eur J Haematol; 2002 Jul; 69(1):27-36. PubMed ID: 12270059
[TBL] [Abstract][Full Text] [Related]
26. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia.
Juliusson G; Heldal D; Hippe E; Hedenus M; Malm C; Wallman K; Stolt CM; Evensen SA; Albertioni F; Tjønnfjord G
J Clin Oncol; 1995 Apr; 13(4):989-95. PubMed ID: 7707128
[TBL] [Abstract][Full Text] [Related]
27. Hairy cell leukemia: results of 2-chlorodeoxyadenosine therapy in Jerusalem.
Dann EJ; Gillis S; Rachmilewitz EA; Barak V; Cass Y; Ruchlemer R; Polliack A
Leuk Lymphoma; 1994; 14 Suppl 1():127-31. PubMed ID: 7820044
[TBL] [Abstract][Full Text] [Related]
28. Real-world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL-CLLEAR study.
Panovská A; Žák P; Jurková T; Arpáš T; Brychtová Y; Vašíková A; Hrabčáková V; Prchlíková A; Filipová M; Doubek M
Hematol Oncol; 2024 May; 42(3):e3280. PubMed ID: 38741354
[TBL] [Abstract][Full Text] [Related]
29. Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia.
Robak T; Wrzesień-Kuś A; Lech-Marańda E; Kowal M; Dmoszyńska A
Leuk Lymphoma; 2000 Sep; 39(1-2):121-9. PubMed ID: 10975390
[TBL] [Abstract][Full Text] [Related]
30. [Hairy cell leukemia therapy by cladribine].
Ogura M
Nihon Rinsho; 2004 Jul; 62(7):1337-42. PubMed ID: 15283153
[TBL] [Abstract][Full Text] [Related]
31. Hairy cell leukemia: clinical presentation and long term follow up after treatment with 2-chlorodeoxyadenosine (2-CdA).
Bilwani F; Usman M; Adil SN; Kakepoto GN; Khurshid M
J Pak Med Assoc; 2005 May; 55(5):212-3. PubMed ID: 15960289
[TBL] [Abstract][Full Text] [Related]
32. Cladribine in the treatment of chronic lymphocytic leukemia.
Robak T
Leuk Lymphoma; 2001 Feb; 40(5-6):551-64. PubMed ID: 11426528
[TBL] [Abstract][Full Text] [Related]
33. Minimal residual disease in hairy-cell leukemia after treatment with 2-chlorodeoxyadenosine.
Konwalinka G; Schirmer M; Hilbe W; Fend F; Geisen F; Knoblechner A; Petzer A; Thaler J
Blood Cells Mol Dis; 1995; 21(2):142-51. PubMed ID: 8846043
[TBL] [Abstract][Full Text] [Related]
34. Five day intermittent vs seven day continuous 2-chlorodeoxyadenosine infusion for the treatment of hairy cell leukemia. A study by Italian Group for the Hairy Cell Leukemia.
Damasio EE; Resegotti L; Masoudi B; Bruni R; Cerri R; Isaza A; Clavio M; Risso M; Rossi E; Spriano M; Truini M
Recenti Prog Med; 1998 Feb; 89(2):68-73. PubMed ID: 9558908
[TBL] [Abstract][Full Text] [Related]
35. Long-term follow-up of patients with hairy cell leukemia after cladribine treatment.
Saven A; Burian C; Koziol JA; Piro LD
Blood; 1998 Sep; 92(6):1918-26. PubMed ID: 9731048
[TBL] [Abstract][Full Text] [Related]
36. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients.
Cheson BD; Sorensen JM; Vena DA; Montello MJ; Barrett JA; Damasio E; Tallman M; Annino L; Connors J; Coiffier B; Lauria F
J Clin Oncol; 1998 Sep; 16(9):3007-15. PubMed ID: 9738569
[TBL] [Abstract][Full Text] [Related]
37. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse.
Tallman MS; Hakimian D; Kopecky KJ; Wheaton S; Wollins E; Foucar K; Cassileth PA; Habermann T; Grever M; Rowe JM; Peterson LC
Clin Cancer Res; 1999 Jul; 5(7):1665-70. PubMed ID: 10430066
[TBL] [Abstract][Full Text] [Related]
38. [Successful ambulatory treatment of patients with hairy-cell leukemia using one cycle of the purine analog cladribine. 'Hemato-oncologic volwassen Nederland' (HOVON) Study Group].
Raemaekers JM; van 't Veer MB; Bogman MJ
Ned Tijdschr Geneeskd; 1996 Aug; 140(31):1600-4. PubMed ID: 8768814
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population.
Madanat YF; Rybicki L; Radivoyevitch T; Jagadeesh D; Dean R; Pohlman B; Kalaycio M; Sekeres MA; Smith MR; Hill BT
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):857-862. PubMed ID: 28778620
[TBL] [Abstract][Full Text] [Related]
40. Development of cladribine at Scripps for hairy cell leukemia and current results.
Torrey ML; Sigal DS; Saven A
Leuk Lymphoma; 2011 Jun; 52 Suppl 2():29-33. PubMed ID: 21504293
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]